Glucocerebrosidase activity and transport to lysosomes in primary macrophages from patients with mutations in the GBA gene

2021 ◽  
Vol 429 ◽  
pp. 119511
Author(s):  
Alena Kopytova ◽  
Mikhail Nikolaev ◽  
Darya Bogdanova ◽  
Artem Izymchenko ◽  
Konstantin Senkevich ◽  
...  
Keyword(s):  
2018 ◽  
Vol 55 ◽  
pp. 45-49 ◽  
Author(s):  
Avner Thaler ◽  
Noa Bregman ◽  
Tanya Gurevich ◽  
Tamara Shiner ◽  
Yonatan Dror ◽  
...  

2020 ◽  
Vol 8 (3) ◽  
Author(s):  
Anna Malekkou ◽  
Ioanna Sevastou ◽  
Gavriella Mavrikiou ◽  
Theodoros Georgiou ◽  
Lluisa Vilageliu ◽  
...  

2015 ◽  
Vol 167 (11) ◽  
pp. 2858-2860 ◽  
Author(s):  
Shagun Aggarwal ◽  
S. Jamal Mohamed Nurul Jain ◽  
Aneek D. Bhowmik ◽  
Ashwani Tandon ◽  
Ashwin Dalal

2019 ◽  
Vol 9 (2) ◽  
pp. 30 ◽  
Author(s):  
Emilia Gatto ◽  
Gustavo Da Prat ◽  
Jose Etcheverry ◽  
Guillermo Drelichman ◽  
Martin Cesarini

In the last years, lysosomal storage diseases appear as a bridge of knowledge between rare genetic inborn metabolic disorders and neurodegenerative diseases such as Parkinson’s disease (PD) or frontotemporal dementia. Epidemiological studies helped promote research in the field that continues to improve our understanding of the link between mutations in the glucocerebrosidase (GBA) gene and PD. We conducted a review of this link, highlighting the association in GBA mutation carriers and in Gaucher disease type 1 patients (GD type 1). A comprehensive review of the literature from January 2008 to December 2018 was undertaken. Relevance findings include: (1) There is a bidirectional interaction between GBA and α- synuclein in protein homeostasis regulatory pathways involving the clearance of aggregated proteins. (2) The link between GBA deficiency and PD appears not to be restricted to α–synuclein aggregates but also involves Parkin and PINK1 mutations. (3) Other factors help explain this association, including early and later endosomes and the lysosomal-associated membrane protein 2A (LAMP-2A) involved in the chaperone-mediated autophagy (CMA). (4) The best knowledge allows researchers to explore new therapeutic pathways alongside substrate reduction or enzyme replacement therapies.


2020 ◽  
Vol 70 ◽  
pp. 36-41 ◽  
Author(s):  
O.E.E. Graham ◽  
T.L. Pitcher ◽  
Y. Liau ◽  
A.L. Miller ◽  
J.C. Dalrymple-Alford ◽  
...  

2007 ◽  
Vol 41 (4) ◽  
pp. 230-236
Author(s):  
N. G. Gorovenko ◽  
N. V. Ol’khovich ◽  
A. M. Nedoboy ◽  
N. O. Pichkur
Keyword(s):  

2011 ◽  
Vol 2011 ◽  
pp. 1-4
Author(s):  
J. J. Sheth ◽  
C. M. Ankleshwaria ◽  
M. A. Mistri ◽  
N. Nanavaty ◽  
S. J. Mehta

A 15-month-old girl, born to the consanguineous parents, was referred with the sign of massive splenomegaly associated with thrombocytopenia and anemia. Plasma Chitotriosidase estimation was carried out as a screening test and was found to be normal with reduced activity ofβ-glucosidase in leucocytes suggestive of Gaucher disease. At the age of 4 years, severe osteoporosis and cardiomegaly with pulmonary congestion were observed in the child. Molecular analysis for GBA gene has revealed homozygous status for L444P (c.1448C) in the proband, whereas parents and two elder sisters were found to be heterozygote. Prenatal study during the fourth pregnancy was carried out from cultured chorionic villi forβ-glucosidase, which was in the carrier range. Further confirmation of the carrier status was carried out from amniotic fluid DNA and was found to be heterozygous for L444P (c.1448C) in theGBAgene. This case demonstrates that children with the sign of splenomegaly with anemia and thrombocytopenia need to be screened for Gaucher disease, and molecular study can further help to confirm the heterozygous status, where prenatal study by enzyme investigation demonstrate heterozygous condition.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4952-4952 ◽  
Author(s):  
Arshi Naz ◽  
Qurat Abedin ◽  
Shariq Ahmed ◽  
Saima Siddiqui ◽  
Tahir Shamsi

Abstract Introduction: Gaucher disease (GD) is one of the lysosomal storage diseases that is rare and inherited autosomal recessively. There is insufficiency of glucocerebrosidase enzyme that leads to the build up of un-degraded substrates in white blood cells causing anemia, hepatosplenomegaly and skeletal disease. This enzyme deficiency is linked with the defect of its gene (GBA) that codes for this enzyme. Initial diagnosis is made by the estimation of glucocerebrosidase level in blood and confirmed by genetic analysis of GBA gene. To identify the mutations of GBA gene in Pakistani patients with GD from different regions of Pakistan. Sampling & methodology: The sample and demographic data was collected in National Institute of Blood Disease and Bone marrow Transplantation after approval of IRB and written informed consent of patients. We collected total 19 blood samples, out of which 5 had Gaucher's disease, 10 samples were parents of the index cases and 4 were control. The methodology consisted of DNA extraction and quantification from peripheral blood. Genetic analysis of coding regions of GBA gene was done via gene amplification, gel electrophoresis and sequencing. Result: Mutation was found in two out of five families that makes the prevalence of GBA gene mutation 40%. These were diagnosed on reduced enzyme levels and found to have L444P (c.1448T>C) mutation in homozygous form in 10th exon of GBA gene. The parents of that patient carried the same mutation in one allele. Rest of the patients who were diagnosed on bone marrow morphology showed no mutation in GBA gene. Conclusion: Our results illustrate that GBA gene mutation was found in those patients who were diagnosed by the estimation of β-glucosidase enzyme levels rather than on bone marrow morphology. In our population, the mutation L444P was found, which is the most frequent gene mutation found in the world. Since this study is conducted in a small number of patients therefore it is recommended that large cohorts of patients should be evaluated in future for genetic mutations among Gaucher's patients in Pakistan Key words: Gaucher disease, storage disorder, GBA gene Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Author(s):  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document